Company profile: Ajax Therapeutics
1.1 - Company Overview
Company description
- Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with SchrΓΆdinger using advanced computational chemistry and structure-based technologies.
Products and services
- Targeted Cytokine Signaling Therapies: Cytokine-targeted therapeutics developed to target cytokine signaling pathways that drive hematologic malignancies, focusing on disease-driving cytokine signaling in hematologic malignancies
- AJ1-10502: A Type II JAK2 inhibitor engineered for treating myeloproliferative neoplasms, exhibiting improved efficacy and selectivity compared with Type I JAK2 inhibitors for targeted suppression of pathogenic signaling
- Partnership with SchrΓΆdinger, Inc.: A structure-based collaboration architecting a pipeline of selectively targeted small molecules for hematologic malignancies using advanced computational chemistry and structure-based technologies
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Ajax Therapeutics
Azeria Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer drug development, creating a pipeline of therapies designed to selectively inhibit pioneer factors to aid treatment of breast and prostate cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Azeria Therapeutics company profile β
Cizzle Biotechnology
HQ: United Kingdom
Website
- Description: Provider of cancer diagnostics for early detection of different forms of lung cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Cizzle Biotechnology company profile β
TomoTherapy
HQ: United States
Website
- Description: Provider of advanced radiation therapy solutions that are developed, manufactured, distributed, marketed and sold for treating a wide variety of cancers. Its ring gantry-based TomoTherapy platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full TomoTherapy company profile β
Lucid Diagnostics
HQ: United States
Website
- Description: Provider of non-invasive, office-based diagnostic solutions for detecting Barrett's esophagus and esophageal adenocarcinoma, including EsoGuard, a DNA test using targeted next-generation sequencing to detect abnormal esophageal cells, and EsoCheck, a non-endoscopic swallowable capsule device that collects esophageal cells for analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Lucid Diagnostics company profile β
Werewolf Therapeutics
HQ: United States
Website
- Description: Provider of oncology biotherapeutics developing systemically delivered, conditionally activated INDUKINE cytokine therapies, including WTX-124 (IL-2), WTX-330 (IL-12), JZP898 (IFNΞ±), WTX-712 (IL-21), and WTX-518 (IL-18), designed to minimize severe toxicities and maximize clinical benefit in multiple or refractory tumor types, and using PREDATOR protein engineering to create immuno-oncology, autoimmune, and inflammatory product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Werewolf Therapeutics company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Ajax Therapeutics
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ajax Therapeutics
2.2 - Growth funds investing in similar companies to Ajax Therapeutics
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Ajax Therapeutics
4.2 - Public trading comparable groups for Ajax Therapeutics
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β